garcinol has been researched along with Parkinson Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, P; Borah, A; Chetia Phukan, B; Deb, S; Dutta, A; Mazumder, MK; Paul, R; Saikia, R; Sandhir, R | 1 |
| Ashok Kumar, K; Chang, YM; Chiu, PL; Ho, TJ; Hsieh, DJ; Huang, CY; Ju, DT; Kuo, WW; Lee, TK; Liao, PH; Liao, SC | 1 |
| Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC | 1 |
| Bhattacharya, P; Borah, A; Deb, S; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC; Sandhir, R | 1 |
1 review(s) available for garcinol and Parkinson Disease
| Article | Year |
|---|---|
Garcinol, a multifaceted sword for the treatment of Parkinson's disease.
Topics: Animals; Histone Acetyltransferases; Humans; Oxidative Stress; Parkinson Disease; Plant Extracts; Terpenes; Treatment Outcome | 2019 |
3 other study(ies) available for garcinol and Parkinson Disease
| Article | Year |
|---|---|
Garcinol blocks motor behavioural deficits by providing dopaminergic neuroprotection in MPTP mouse model of Parkinson's disease: involvement of anti-inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Neuroprotection; Parkinson Disease; Substantia Nigra; Terpenes | 2022 |
Garcinol protects SH-SY5Y cells against MPP+-induced cell death by activating DJ-1/SIRT1 and PGC-1α mediated antioxidant pathway in sequential stimulation of p-AMPK mediated autophagy.
Topics: 1-Methyl-4-phenylpyridinium; AMP-Activated Protein Kinases; Antioxidants; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Neuroblastoma; Neurodegenerative Diseases; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Sirtuin 1 | 2023 |
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Topics: Humans; Inflammation; Isoxazoles; Levodopa; Ligands; Molecular Conformation; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Parkinson Disease; Phytochemicals; Phytotherapy; Reactive Oxygen Species; Terpenes; Zonisamide | 2018 |